Experimental Flu Vaccine Technique Could Reduce Time Needed To Develop New Shots For Humans

“An experimental vaccine based on a molecule related to DNA protects animals against influenza and may one day offer an ultra-rapid way to develop new shots for humans, German scientists reported on Sunday,” Reuters reports (Hirschler, 11/25). “In a first for any infectious disease, a vaccine against flu has been made out of messenger RNA (mRNA) — the genetic material that controls the production of proteins,” New Scientist writes, adding, “Unlike its predecessors, the new vaccine may work for life, and it may be possible to manufacture it quickly enough to stop a pandemic” (Mackenzie, 11/25).

“Reporting their results in the journal Nature Biotechnology, [Lothar Stitz of Friedrich-Loeffler-Institut and colleagues] calculated that a completed vaccine could be produced within six to eight weeks of the genetic code of a flu virus strain being published,” Reuters notes, adding, “In contrast, growing vaccines in fertilized chicken eggs can take up to six months, while using cell cultures may reduce that by up to eight to 10 weeks” (11/25). “Finding a rapid cure for the flu each season is critical given the ever-changing character of the virus,” GlobalPost notes (11/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.